Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | EGLN1 | Q9GZT9 | 9/20 | 0.50 |
| ▸ | BRD4 | O60885 | 2/20 | 0.48 |
| ▸ | BRD2 | P25440 | 1/20 | 0.48 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.48 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2281397 | 0.81 | EGLN1 (0.58) | MEN1KMT2AALDH1A1EGLN1BRD4 | |
| SCHEMBL2285307 | 0.81 | HSP90AA1 (0.52) | MEN1KMT2AALDH1A1EGLN1BRD4 | |
| SCHEMBL12376648 | 0.78 | RIPK1 (0.50) | MEN1KMT2AALDH1A1EGLN1SMN1; SMN2 | |
| SCHEMBL13101588 | 0.78 | BRD4 (0.73) | MEN1KMT2AALDH1A1BRD4BRD2 | |
| SCHEMBL12376658 | 0.76 | CNR2 (0.37) | MEN1KMT2AALDH1A1BRD4 | |
| SCHEMBL13101593 | 0.74 | ALDH1A1 (0.39) | MEN1KMT2AALDH1A1EGLN1SMN1; SMN2 | |
| SCHEMBL13701754 | 0.73 | BRD4 (0.73) | ALDH1A1BRD4BRD2BRD3BRDT | |
| SCHEMBL13101585 | 0.72 | ALDH1A1 (0.51) | MEN1KMT2AALDH1A1EGLN1BRD4 | |
| SCHEMBL12561531 | 0.72 | RAB9A (0.46) | MEN1KMT2ASMN1; SMN2KDM4EHTT | |
| SCHEMBL13906172 | 0.72 | RAB9A (0.48) | MEN1KMT2ASMN1; SMN2KDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-7723330-B2 | Heterobicyclic pyrazole compounds and methods of use | ARRAY BIOPHARMA INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | GENENTECH, INC. | 2007-10-11 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | MEN1 3149/4885KMT2A 4415/4885ALDH1A1 1635/4885 |
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ROR1, CYP11B1, CYP11B2 | MEN1 2329/4885KMT2A 4800/4885ALDH1A1 1929/4885 |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | ROR1, CYP11B1, CYP11B2 | MEN1 2329/4885KMT2A 4800/4885ALDH1A1 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.